Semax is a synthetic heptapeptide derived from the ACTH(4-7) sequence — a fragment of adrenocorticotropic hormone — that has been developed and clinically used in Russia since the 1980s for stroke rehabilitation, cognitive enhancement, and neuroprotection. Its primary mechanism of action involves upregulation of brain-derived neurotrophic factor (BDNF), the key growth factor responsible for neuroplasticity, synaptic strengthening, and neuronal survival.
The BDNF Mechanism
BDNF is often described as "Miracle-Gro for the brain." It promotes the growth, maintenance, and survival of neurons; strengthens synaptic connections; and is the primary molecular substrate of learning and memory. Semax increases BDNF expression in the hippocampus and prefrontal cortex — the brain regions most critical for memory formation and executive function — through activation of the TrkB receptor pathway.
Brain Fog: The Mechanism of Action
Brain fog — the subjective experience of cognitive sluggishness, difficulty concentrating, and impaired mental clarity — is often associated with neuroinflammation, reduced cerebral blood flow, and impaired neurotransmitter signaling. Semax addresses all three: it has anti-inflammatory effects in the CNS, improves cerebral blood flow through nitric oxide modulation, and enhances dopaminergic and serotonergic signaling in the prefrontal cortex.
Intranasal Delivery: The CNS Advantage
The intranasal route is preferred for Semax because it allows direct transport along the olfactory nerve to the CNS, bypassing the blood-brain barrier entirely. Studies have shown that intranasal Semax reaches the brain within minutes of administration, with peak CNS concentrations achieved in 20-30 minutes. This makes it uniquely suited for acute cognitive enhancement applications — dosing before demanding cognitive tasks for immediate effect.